{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "6619578",
  "DateCompleted": {
    "Year": "1983",
    "Month": "11",
    "Day": "23"
  },
  "DateRevised": {
    "Year": "2019",
    "Month": "05",
    "Day": "11"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [],
    "Journal": {
      "ISSN": "0022-1899",
      "JournalIssue": {
        "Volume": "148",
        "Issue": "3",
        "PubDate": {
          "Year": "1983",
          "Month": "Sep"
        }
      },
      "Title": "The Journal of infectious diseases",
      "ISOAbbreviation": "J Infect Dis"
    },
    "ArticleTitle": "Efficacy and tolerance of intranasally applied recombinant leukocyte A interferon in normal volunteers.",
    "Pagination": {
      "StartPage": "535",
      "EndPage": "542",
      "MedlinePgn": "535-42"
    },
    "Abstract": {
      "AbstractText": [
        "The prophylactic effect of recombinant leukocyte A interferon (rIFN-alpha A) (dosage, 10 X 10(6) units per day for four days) against illness and infection in 26 volunteers challenged with rhinovirus type 13 was measured in a double-blind, placebo-controlled study. Significant reductions in illness frequency (7.1% vs 66.7%, P less than 0.003), mean symptom scores, nasal secretion weights, and frequency of virus isolation were observed. However, there was no significant difference in infection rates between rIFN-alpha A- and placebo-treated volunteers. Late posttreatment virus shedding, which was unassociated with late illness, was observed in the rIFN-alpha A-treated group. In two double-blind, placebo-controlled tolerance studies of rIFN-alpha A, five (26%) of the 19 volunteers treated with rIFN-alpha A reported bleeding mixed with mucous nasal discharge and had documented superficial erosions of the nasal mucosa. Future studies will be necessary to evaluate lower doses and/or alternative treatment schedules for improved tolerance and continued efficacy."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Samo",
        "ForeName": "T C",
        "Initials": "TC"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Greenberg",
        "ForeName": "S B",
        "Initials": "SB"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Couch",
        "ForeName": "R B",
        "Initials": "RB"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Quarles",
        "ForeName": "J",
        "Initials": "J"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Johnson",
        "ForeName": "P E",
        "Initials": "PE"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Hook",
        "ForeName": "S",
        "Initials": "S"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Harmon",
        "ForeName": "M W",
        "Initials": "MW"
      }
    ],
    "GrantList": [
      {
        "GrantID": "RR-00350",
        "Acronym": "RR",
        "Agency": "NCRR NIH HHS",
        "Country": "United States"
      }
    ],
    "PublicationTypeList": [
      "Clinical Trial",
      "Comparative Study",
      "Controlled Clinical Trial",
      "Journal Article",
      "Research Support, Non-U.S. Gov't",
      "Research Support, U.S. Gov't, P.H.S."
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "J Infect Dis",
    "NlmUniqueID": "0413675",
    "ISSNLinking": "0022-1899"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "DNA, Recombinant"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Interferon Type I"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Administration, Intranasal"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Adolescent"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Adult"
    },
    {
      "QualifierName": [
        "prevention & control"
      ],
      "DescriptorName": "Common Cold"
    },
    {
      "QualifierName": [],
      "DescriptorName": "DNA, Recombinant"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Double-Blind Method"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Drug Evaluation"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "administration & dosage",
        "adverse effects",
        "therapeutic use"
      ],
      "DescriptorName": "Interferon Type I"
    },
    {
      "QualifierName": [
        "analysis"
      ],
      "DescriptorName": "Nasal Mucosa"
    }
  ]
}